This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Artemotil
DrugBank Accession Number
DB13851
Background

Artemotil, also known as β-arteether, is a semi-synthetic derivative of artemisinin and a fast acting blood schizonticide specifically indicated for the treatment of chloroquine-resistant Plasmodium falciparum malaria and cerebral malaria cases.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 312.406
Monoisotopic: 312.193674002
Chemical Formula
C17H28O5
Synonyms
  • Arteether
  • Artemotil
  • beta-Arteether
  • beta-Dihydroartemisinin ethyl ether
  • Dihydroartemisinin ethyl ether
External IDs
  • SM 227

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetophenazineThe risk or severity of QTc prolongation can be increased when Artemotil is combined with Acetophenazine.
AlimemazineThe risk or severity of QTc prolongation can be increased when Artemotil is combined with Alimemazine.
ArtemetherThe risk or severity of QTc prolongation can be increased when Artemotil is combined with Artemether.
ButaperazineThe risk or severity of QTc prolongation can be increased when Artemotil is combined with Butaperazine.
ChlorpromazineThe risk or severity of QTc prolongation can be increased when Artemotil is combined with Chlorpromazine.
DapsoneThe risk or severity of adverse effects can be increased when Artemotil is combined with Dapsone.
FluphenazineThe risk or severity of QTc prolongation can be increased when Artemotil is combined with Fluphenazine.
LumefantrineThe risk or severity of QTc prolongation can be increased when Artemotil is combined with Lumefantrine.
MefloquineMefloquine may increase the QTc-prolonging activities of Artemotil.
MesoridazineThe risk or severity of QTc prolongation can be increased when Artemotil is combined with Mesoridazine.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

ATC Codes
P01BE04 — Artemotil
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
XGL7GFB9YI
CAS number
75887-54-6
InChI Key
NLYNIRQVMRLPIQ-XQLAAWPRSA-N
InChI
InChI=1S/C17H28O5/c1-5-18-14-11(3)13-7-6-10(2)12-8-9-16(4)20-15(19-14)17(12,13)22-21-16/h10-15H,5-9H2,1-4H3/t10-,11-,12+,13+,14+,15-,16-,17-/m1/s1
IUPAC Name
(1R,4S,5R,8S,9R,10S,12R,13R)-10-ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane
SMILES
[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@H](OCC)[C@@H]2C)O4

References

General References
Not Available
ChemSpider
2272064
BindingDB
50426305
ChEBI
135335
ChEMBL
CHEMBL301267
ZINC
ZINC000008214360
Wikipedia
Artemotil

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.276 mg/mLALOGPS
logP3.52ALOGPS
logP3.84ChemAxon
logS-3ALOGPS
pKa (Strongest Basic)-3.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area46.15 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity79.41 m3·mol-1ChemAxon
Polarizability34.08 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at June 23, 2017 20:49 / Updated at February 21, 2021 18:54